益气安神汤联合常规化疗方案治疗气血两虚型乳腺癌的临床效果OA
Clinical Efficacy of Yiqi Anshen Decoction Combined with Conventional Chemotherapy in Breast Cancer Patients with Deficiency of Qi and Blood
目的:探讨益气安神汤联合常规化疗方案对气血两虚型乳腺癌患者疗效、免疫及人表皮生长因子受体2(Her-2)、拓扑异构酶Ⅱ(TOPⅡ)的影响.方法:选取 2020 年 1 月—2022 年 1 月攀枝花市中西医结合医院收治的 84 例气血两虚型乳腺癌患者作为研究对象.采用随机数表法将其分为两组,对照组 42 例采用常规化疗方案治疗,观察组 42 例采用益气安神汤联合常规化疗方案治疗.比较两组临床疗效,治疗前后免疫功能、Her-2、TOPⅡ阳性表达及不良反应发生率.结果:观察组肿瘤控制率为 78.57%,高于对照组的 57.14%,差异有统计学意义(P＜0.05).治疗后,两组CD4+、CD4+/CD8+水平均升高,CD8+水平均降低,且观察组CD4+、CD4+/CD8+水平比对照组高,CD8+水平比对照组低,差异有统计学意义(P＜0.05).治疗后,两组Her-2、TOPⅡ阳性表达率低于治疗前,且观察组Her-2、TOPⅡ阳性表达率分别为 23.81%、21.43%,均低于对照组的 45.24%、42.86%,差异有统计学意义(P＜0.05).观察组不良反应发生率为 9.52%,低于对照组的 26.19%,差异有统计学意义(P＜0.05).结论:益气安神汤联合常规化疗方案治疗气血两虚型乳腺癌的效果显著,能有效改善患者免疫功能,降低Her-2、TOPⅡ阳性表达,且不良反应发生少,安全性良好.
Objective:To explore the effects of Yiqi Anshen Decoction combined with conventional chemotherapy on the efficacy,immunity and human epidermal growth factor receptor 2(Her-2),topoisomerase Ⅱ(TOPⅡ)in the treatment of breast cancer patients with Qi and blood deficiency.Method:Eighty-four cases of breast cancer patients with Qi and blood deficiency type admitted to Panzhihua Integrated Traditional Chinese and Western Medicine Hospital from January 2020 to January 2022 were selected as the study subjects,and they were divided into two groups by random number table method.The 42 patients in the control group were treated with conventional chemotherapy regimen,and the 42 cases in the observation group were treated with Yiqi Anshen Decoction combined with conventional chemotherapy regimen.The clinical efficacy of the two groups,immune function,Her-2,TOPⅡ positive expression before and after treatment and the incidence of adverse reactions were compared.Result:The tumor control rate in the observation group was 78.57%,which was higher than 57.14%in the control group,the difference was statistically significant(P＜0.05).After treatment,the levels of CD4+,CD4+/CD8+in both groups were increased,the CD8+decreased,and the levels of CD4+,CD4+/CD8+in the observation group were higher than those in the control group,and the level of CD8+was lower than that in the control group,the differences were statistically significant(P＜0.05).After treatment,the positive expression rates of Her-2 and TOPⅡ in both groups were lower than those of before treatment,and Her-2 and TOPⅡ in the observation group were 23.81%and 21.43%,respectively,which were lower than 45.24%and 42.86%in the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the observation group was 9.52%,which was lower than 26.19%in the control group,the difference was statistically significant(P＜0.05).Conclusion:Yiqi Anshen Decoction combined with conventional chemotherapy has a significant effect on breast cancer patients with Qi and blood deficiency type,which can effectively improve the immune function of patients,reduce the positive expression of Her-2 and TOPⅡ,with less adverse reactions and good safety.
李铁莲;雷小林;文雯;陈泓羽
攀枝花市中西医结合医院 四川 攀枝花 617000
乳腺癌气血两虚型益气安神汤化疗免疫功能人表皮生长因子受体2拓扑异构酶Ⅱ
Breast cancerQi and blood deficiency typeYiqi Anshen DecoctionChemotherapyImmunityHuman epidermal growth factor receptor 2Topoisomerase Ⅱ
《中外医学研究》 2024 (035)
31-34 / 4
评论